Neurocrine Biosciences, Inc. Forecast, price target & analysts
Neurocrine Biosciences, Inc. Target price 2026 - Analyst rating & recommendation
Neurocrine Biosciences, Inc. Classifications & Recommendation
Neurocrine Biosciences, Inc. Price Target
| Target Price | $217.26 |
| Price | $138.40 |
| Potential |
56.98%
register free of charge
|
| Number of Estimates | 31 |
|
31 Analysts have issued a price target Neurocrine Biosciences, Inc. 2027 .
The average Neurocrine Biosciences, Inc. target price is $217.26.
This is
56.98%
register free of charge
$261.45
88.91%
register free of charge
$166.65
20.41%
register free of charge
|
|
| A rating was issued by 36 analysts: 31 Analysts recommend Neurocrine Biosciences, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2027 of
56.98%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.86 | 3.98 |
| 21.45% | 39.10% | |
| EBITDA Margin | 23.30% | 25.46% |
| 10.04% | 9.25% | |
| Net Margin | 16.73% | 18.29% |
| 15.46% | 9.32% |
31 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2026 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2026. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
31 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2026. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 4.67 | 7.16 |
| 41.95% | 53.32% | |
| P/E | 19.32 | |
| EV/Sales | 3.44 |
31 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
Current Neurocrine Biosciences, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 03 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
